Predicting Clinical Outcomes in *Helicobacter pylori*-positive Patients using Supervised

Learning through the Integration of Demographic and Genomic Features

Venkatesh Narasimhan[1,**] (https://orcid.org/0009-0002-6589-6197)*,* Sreya Pulakkat Warrier[2,**]

(https://orcid.org/0009-0008-9048-2862), Jobin Jacob John[1] (https://orcid.org/0009-0009-7745-

192X), Monisha Priya T[1], Niriksha Varadaraj[1], Greeshma Grace Thomas[3], Balaji

Veeraraghavan[1,*]

[1] Department of Clinical Microbiology, Christian Medical College and Hospital, Vellore, India

[2] School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India

[3] Department of General Medicine, Christian Medical College and Hospital, Vellore, India

[*] Corresponding author

[**] Authors contributed equally

Correspondence:

Prof. Balaji Veeraraghavan

Department of Clinical Microbiology,

Christian Medical College & Hospital Vellore,

India

Email: vbalaji@cmcvellore.ac.in

ORCID ID: https://orcid.org/0000-0002-8662-4257

Abstract

Background:

Helicobacter pylori (H. pylori) infection is widespread globally and is linked to outcomes

ranging from chronic gastritis to gastric cancer. However, only a minority of infected individuals

progress to malignancy, influenced by a mix of bacterial, host, and environmental factors.

Current predictive approaches are limited due to relying mainly on clinical and lifestyle data.

Genomic approaches have been sparsely used, and thus their incorporation into machine learning

models could ensure early and personalized detection. This study aimed to evaluate the impact of

integrating host metadata with genomic features from *H. pylori* to predict gastric cancer

outcomes and identify associated variables.

Methods:

1,363 publicly available *H. pylori* genomes with associated host information between 1991 and

2024 were collected from NCBI and EnteroBase. Demographic features, virulence genes,

sequence-derived and variant-based features were extracted. Machine learning models were then

developed to classify infection outcomes into gastric cancer and non-gastric cancer. Logistic

regression, an interpretable baseline model, was compared against higher-performance ensemble

models (XGBoost, Random Forest). Model performance was assessed using recall, precision,

AUROC, and AUPRC curves.

Results:

The logistic regression model achieved a recall of 0.736 (95% CI: 0.644-0.831) for gastric cancer

and an AUROC of 0.888 (95% CI: 0.843-0.929). Both XGBoost and Random Forest models

outperformed the baseline model with AUROC values ranging from 0.950-0.954 (95% CI:

0.904-0.976). Black-box model recall for gastric cancer detection improved compared to the

baseline by 8.3% for XGBoost (0.797, 95% CI: 0.711-0.877), and 11.4% for Random Forest

(0.820, 95% CI: 0.734-0.896). Across models, patient age consistently emerged as the strongest

predictor of gastric cancer, with several sequence-derived genomic features beyond pre-

established virulence genes contributing to the infection outcome differences.

Conclusion:

This study demonstrates that combining pathogen genomics with host demographics uncovers

novel risk factors and ensures early detection with high predictive power. The use of

explainability methods like SHAP allows for greater interpretability by clinical professionals and

improves informed decision-making processes. Validation and translation into clinical practice

can be carried out with broader, diverse datasets along with the inclusion of additional host and

lifestyle variables.

Keywords: *Helicobacter pylori, Gastric cancer, Supervised machine learning, Genomic*

sequence-based feature extraction, Ensemble learning, SHAP interpretability, machine learning

1. Background:

Helicobacter pylori (*H. pylori*) is a highly motile, helical and gram-negative bacterium that is known for colonising the human gastrointestinal tract, and primarily associated with chronic active gastritis. *H. pylori* infection is strongly linked to the development of serious gastrointestinal diseases and accounts for up to 90% of duodenal ulcers, and around 80% of stomach ulcers and 90% of gastric carcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma cases[1]. In accordance with the burden posed by these diseases, the World Health Organisation (WHO) recommended prioritising *H. pylori* eradication strategies in 2014 to help in reducing stomach cancer mortality rates worldwide.

At the global level, *H. pylori* affects almost half of the world's population, and has a disproportionately high prevalence of around 50.8% in resource-limited regions, which are often characterized by suboptimal sanitation and healthcare access [2]. Gastric cancer is also relatively uncommon among younger individuals with fewer than 10% of cases occurring before the age of 45. There is a sharp spike in the lifetime risk of gastric cancer for infected individuals, with the probability being nearly double compared to uninfected individuals[3].

The clinical outcomes of *H. pylori* infection considerably vary across geographic populations and are influenced by a variety of factors like bacterial genotype diversity, host immune responses, and environmental factors. The bacterium's ability to thrive in the acidic gastric environment has been linked to specialized virulence mechanisms. These help it facilitate persistent colonization and chronic inflammation, which dictate the host's gastritis phenotype and disease trajectory. There are several *H. pylori* genes that have been implicated in the development of severe gastroduodenal diseases. The cytotoxin-associated gene A (*cagA*) gene, encoding the CagA protein is found at the end of the cag pathogenicity island (cagPAI), and is

associated with increased cancer risk and severe infections[4]. The marker is more discriminative

in Western countries on account of only around 60% of strains carrying *cagA*, compared to over

90% of East Asian strains being *cagA*-positive[5]. The vacuolating cytotoxin A (*vacA)* gene

encodes the vacA cytotoxin which helps in inducing vacuole formation, autophagy modulation

and evading immune responses[6,7]. Strains harbouring the *vacA* s1/m1/*cagA+* genotype show a

4.8-fold increased risk of progressing to precancerous lesions compared to *vacA* s2/m2/*cagA-*

strains[8]. The *babA2* gene, encoding the blood group antigen binding adhesin (BabA) that binds to

mucosal Lewis[b] blood group antigens, helps in aiding colonisation and increasing bacterial load[9].

The triple positive genotype possessing *babA2, vacA* s1 and *cagA* genes offer stronger gastric

cancer discrimination than *vacA* and *cagA* alone[10]. The outer inflammatory protein A (*oipA*) gene

promotes epithelial attachment, IL-8-mediated inflammation and disruption of cell turnover, and

is often found co-expressed with other virulence genes[11–16]. *homB* gene has been found to aid

adhesion and IL-8 induction, while *sabA* promotes neutrophil activation and inflammation

through binding to sialylated Lewis antigens (sLe^X)[17–20].

The *htrA* gene is closely linked to tumor suppression and metastasis, and the *iceA1* gene has also

been significantly associated with gastric cancer[21–23]. The *hopQ* type I allele is linked with

increased gastric cancer and gastric ulcer risk, especially in East Asia where it is commonly

present with *cagA*, while type II *hopQ* is more frequent in Western strains[24].

Diagnosing *H. pylori* infection is reliant on a combination of methods. These include invasive

methods such as endoscopy and biopsy, and non-invasive approaches like urea breath tests, stool

antigen tests, and serological assays. The diagnostic tool choice is guided by a lot of factors like

patient history, clinical presentation and resource availability. Typical eradication therapy

usually involves a potent acid suppressant with antibiotics and bismuth compounds in some

cases. Curbing the alarming rise of antibiotic resistance among *H. pylori* strains relies on

judicious antibiotic use and resistance surveillance methods[25].

Understanding the genetic diversity of *H. pylori* and its associated phenotypic variability can be

used to build accurate prediction models using machine learning approaches. This could help

improve therapeutic approaches by stratifying patients based on infection outcomes[26].

Despite there being some studies on predicting gastric cancer in *H. pylori* infected patients, they

have primarily relied on clinical and lifestyle data and often included patients without confirmed

H. pylori infection[27–29]. To our knowledge, there have been no studies that have integrated

clinical host metadata, aggregated variant annotation features from VCF files, virulence gene

presence and absence data, and sequence-derived features from *H. pylori* genomes in a single,

unified machine learning framework. In this study, we focused solely on *H. pylori* infected

patients and developed a machine learning pipeline to classify gastric cancer versus non-gastric

cancer cases using a combination of the above mentioned features. A comprehensive summary of

the study workflow is provided in Figure 1. We aim to provide researchers with novel genomic

markers that can be further analyzed for causation in wider studies, along with the validation of

established causative factors of gastric cancer like age. We hope this will improve stratification

of infection responses and prevent delayed care for high-risk patients, along with increasing

physician trust and augmenting decision-making.

Figure 1: Overview of the machine learning workflow for classification of gastric cancer and non-gastric cancer using *H. pylori* genomes and clinical data. The workflow consists of three stages, depicted from left to right, with arrows indicating the flow of the stages: (1) Data collection and quality control, host clinical metadata and *H. pylori* whole genomes are integrated and filtered for quality, and bioinformatics analysis (variant calling); (2) Feature extraction and data preprocessing (normalization, one-hot encoding, label encoding), including clinical features, variant-level features from VCF files, and genome sequence-derived features and presence/absence data of *H. pylori* virulence genes to construct the final dataset, followed by data preprocessing; and (3) Model training, evaluation and explanation, involving binary classification using white-box (Logistic Regression) and black-box models (XGBoost and Random Forest) with 10-fold cross-validation and hyperparameter bayesian optimization, performance evaluation using AUROC and AUPRC metrics, and finally feature importance interpretation.

2. Methods

2.1 Data Collection

Helicobacter pylori genomes from NCBI and Enterobase were filtered for the presence of host-age, host-sex, host geographical location and disease phenotype information, resulting in 1587 genomes. The genomes from Enterobase were pre-assembled and case controls were excluded. NCBI Biosample Metadata was similarly downloaded and case controls and duplicates were excluded. Pre-assembled genomes from GenBank and RefSeq were downloaded using NCBI Datasets, while Sequence Read Archive (SRA) database sequences consisting of high-throughput short reads were downloaded through Fastq-dump from SRA Toolkit (version 3.2.1) .

2.2 Genome Quality Control and Assembly

The unassembled short reads were assembled with the help of SKESA (version 2.4.0). Quality control was carried out using Pathogenwatch (version 23.2.1) to filter out contaminated genomes belonging to the wrong species, resulting in 781 Enterobase downloaded genomes and 582 genomes from NCBI. The final dataset consisted of 1,363 genomes which passed the quality control step and were collected in the years spanning from 1991-2024.

2.3 Feature Extraction

In order to develop a machine learning model well-equipped to predict gastric cancer status in *H. pylori* infected patients, a diverse set of features was included in the final dataset. These included clinical metadata from NCBI and Enterobase, gene presence and absence information obtained with the help of BLASTN-based homology searches, aggregated variant annotation features from VCF files and genome-derived sequence descriptors.

2.4 Clinical and Epidemiological features:

The clinical metadata associated with each *H.pylori* genome was collected from Enterobase and NCBI databases (Supplementary Table S1). The age, sex, and geographical location of the host along with their disease phenotype was extracted. With the help of clinical expertise, this disease phenotype was converted into one of two labels: gastric cancer and non-gastric cancer. This served as the label for the machine learning model and was appropriately encoded as mentioned in later sections.

2.5 Gene Presence and Absence features:

In addition to the clinical metadata, gene variant presence and absence information was also

derived by identifying relevant gene variants associated with gastric and non-gastric cancer

phenotype through exhaustive literature review.

These reference gene variant sequences linked to certain strains were extracted from a collection

of genomes. These included cagA, babB, oipA, sabA and vacAs1m1 from *H.pylori* strain 60190;

babA2 from *H.pylori* strain ATCC 43504; hopQI from *H.pylori* strain J99; homB, hrgA, htrA,

iceA1 from *H.pylori* strain 26695; hopQII from Tx30a.

Each of these assembled genomes were formatted into a separate BLAST compatible database.

Each gene sequence was queried against each of the 1363 genome databases with the help of

BLASTN (version 2.12.0). A gene was considered present in a genome if the top hit satisfied the

below criteria:

● Percentage identity >= 90%

● Query coverage >= 80%

● E-value <= 1e-5

The presence of each gene was encoded as 1 and the absence as 0, resulting in a binary feature

set (Supplementary Table S2). These thresholds were selected in order to balance sensitivity and

specificity and to ensure accurate homologous gene detection by minimizing false positives.

2.6 Assembled Genomic Sequence Derived features:

To capture additional biological information, numerical sequence descriptors were extracted

directly from the genomes using two Python-based packages, iFeatureOmega (version 1.0.2) and

MathFeature (version 1.0) (Table 1).

These sequence-based features were computed by the packages at a contig level, which were

then averaged in a length-weighted manner to generate a single representative feature vector per

genome (Supplementary Table S3).

Specifically, for a given feature f, the genome-level feature average F was calculated as:

205
$$F = \frac{\sum_{i=1}^{n} f_i \times l_i}{\sum_{i=1}^{n} l_i} \qquad (1)$$

where:

● f_i is the feature value for the i-the contig,

● l_i is the length (in base pairs) of the i-th contig,

● and n is the total number of contigs for that genome.

This method ensured that longer contigs which typically provide more reliable sequence

information would contribute proportionally to the final feature representation.

216   Table 1: Feature types utilised in this study and the respective package

Package	Feature type
iFeatureOmega	Z-curve (144-bit)
	Kmer Type 1
	RCKmer Type 1
	Nucleic Acid Composition (NAC)
	Multivariate Mutual Information (MMI)
	CKSNAP type 1
MathFeature	Shannon Entropy
	ORF-Based Features

2.7 Variant-Based Features from VCF files:

Variant level features were extracted from genome-wide mutation profiles to include impact

about sequence variation and their functional effects. The strain 26695 was used as a reference to

call variants using Snippy (version 4.6.0), a rapid bacterial variant calling pipeline, on the

assembled *H.pylori* genomes. Following variant calling, the Snippy-created VCF files were

passed to another tool known as bcftools (version 1.2.1) for identifying the number of SNPs and

MNPs. Using bcftools' (version 1.2.1) stats module, the raw counts of the following features

were extracted SNPs, MNPs, Indels, and all possible nucleotide changes (e.g.,A → T, T → C,

etc.). The variant effect functional annotations were also extracted from the VCF files to classify

sequence changes based on their predicted effects on coding regions. The total counts of each

variant effect were calculated per genome. These included types of mutations such as missense

variants, frameshift mutations, mutations that affect start codons and combinations of these. For

each genome, the number of variants falling into each functional category was counted and

recorded as individual features.

These metrics were aggregated into per-genome features to help capture unexplored signals

associated with the gastric cancer phenotype (Supplementary Table S4).

2.8 Data Preprocessing:

A comprehensive series of steps were carried out to preprocess the dataset to make it amenable

for model training (Supplementary Table S5). The versions of scikit-learn, Pandas, matplotlib

and Python used were 1.6.1, 2.2.3, 3.10.1 and 3.12.3.

Minor corrections were carried out to standardise categorical entries including correcting

typographical errors, standardising the case of the characters and removing entries where the host

sex was indeterminate, resulting in 1362 genomes.

The dataset was then split into training sets and test sets using the StratifiedShuffleSplit module

from scikit-learn (version 1.6.1) (80% training set, 20% test set). For the input features,

preprocessing for the input features involved normalisation using the MinMaxScaler module and

one-hot encoding using the OneHotEncoder module in scikit-learn.

Label encoding was used to convert the categorical class labels of 'Gastric cancer' and 'Non-

gastric cancer' into numeric representations using the LabelEncoder module in scikit-learn. Since

the LabelEncoder module encodes the classes in alphabetical order, 'Gastric cancer' was

encoded as 0 and 'Non-gastric cancer' was encoded as 1.

The same processes of normalisation and encoding were also applied separately to the test set to

ensure that the preprocessing steps were consistent across training and test datasets. The

transformations performed on the test set were done independently to prevent any form of

information leakage. The resulting dataset was rendered suitable for further feature selection and

model training steps.

2.9 Feature Selection:

Feature selection was only performed for the black-box models (XGBoost and Random Forest)

to mitigate overfitting, enhance generalization and improve the model's explainability. In

contrast, the baseline model (Logistic Regression) was trained on the complete feature set to

provide a consistent benchmark for comparison. The ShapRFECV module in the probatus

package (version 3.1.2) which performed recursive feature elimination based on SHAP

importance scores was used to select features. The features with the lowest SHAP scores were

iteratively removed to get the final feature set.

The optimal feature subset was selected by maximizing the base model's (LightGBMClassifier)

performance used for performing feature selection. This resulted in a final set of 93 features,

which was used to subset the original dataset.

2.10 Model Training and Development

A Logistic Regression classifier was trained as the baseline model and chosen for its white-box

functionality and for its ease of interpretability. A random state of 26 was used to maintain

reproducibility.

Class imbalance in the dataset was handled using SMOTE-NC. It was preferred over SMOTE

due to its ability to handle both categorical and continuous features by generating synthetic

samples for the minority class while retaining the categorical nature of categorical variables. It

was applied within a generated pipeline to the training folds within each cross-validation split to

ensure that synthetic samples did not influence the model evaluation step on the validation step.

The full model training pipeline was built using imblearn's make_pipeline function and had

SMOTE-NC and Logistic Regression classifier (with random state=26 to maintain

reproducibility) as its two components.

Cross-validation was carried out using StratifiedShuffleSplit by splitting the dataset into 10 folds

for robust evaluation, with the stratification step preserving the class distribution during both

model training and evaluation. Recall was selected as the scoring metric to prioritise accurate

identification of gastric cancer cases and minimise any false negatives. After cross-validation,

the model was refitted on the entire training dataset to optimise its performance before applying

it to the test set.

An XGBoost classifier was trained as the black-box model and chosen for its black-box high

performance. The steps taken for preprocessing the dataset were identical to the baseline model,

including the chosen random state.

Categorical feature indices were identified and used with SMOTE-NC and a pipeline to first

oversample and then train an XGBClassifier on the reduced feature set. Hyperparameter tuning

was carried out using the BayesSearchCV function from scikit-optimize package, which employs

Bayesian optimization to automatically search for the best hyperparameters to enhance the

performance of the model.

Probability calibration was also performed on the XGBoost classifier using

CalibratedClassifierCV specifically using sigmoid regression to ensure that the predicted

probabilities better reflected the true likelihood of an outcome and Brier score was computed to

quantify the accuracy of these calibrated probabilities, with lower scores indicating better

calibration.

$$Brier\ Score\ = \frac{1}{N}\sum_{i=1}^{N}(f_i - o_i) \qquad (2)$$

Where:

● N = total number of samples

● f_i = predicted probability of sample i

● o_i = observed outcome for sample i (0 = gastric cancer, 1 = non-gastric cancer)

After cross-validation, the model was refitted on the entire training dataset to optimise its

performance before applying it to the test set. A Random Forest black-box classifier was trained

and evaluated in the same manner as the XGBoost model. All the trained models were evaluated

on the encoded test set using the trained pipeline to assess its generalisation abilities on unseen

data.

2.11 Model Evaluation:

A classification report was generated in order to provide the values of key metrics like precision,

recall and F1-score. These metrics were calculated for both the positive class (gastric cancer) and

the negative class (non-gastric cancer), along with their 95% confidence intervals obtained using

bootstrap resampling. Specificity was explicitly reported for the negative class, while sensitivity

(recall) was reported for the positive class.

319
$$Precision = \frac{TP}{TP + FP} \qquad (4)$$

320
$$Recall\ (Sensitivity) = \frac{TP}{TP + FN} \qquad (5)$$

322
$$F1 = 2 \times \frac{Precision \times Recall}{Precision + Recall} \qquad (6)$$

Where:

● *TP* = True Positives

● *FP* = False Positives

● *FN* = False Negatives

Along with this, the Receiver Operating Characteristic (ROC) curve was plotted to detect a

trade-off between correct identification of true positives and minimization of false positives. The

Area Under the Curve (AUC) score was used to summarise the ROC curve, with an AUC value

closer to 1 indicating better model performance, and its 95% confidence interval was also

calculated. The Area Under the Precision-Recall curve (AUPRC) was also plotted to visualise

the proportion of true positives among all predicted positives against the proportion of actual

positives identified by the model. The positive class was specified as gastric cancer, with the

negative class being non-gastric cancer. Average precision (AP) score, computed as the area

under the PR curve, offers a more effective evaluation than the ROC curve due to its sensitivity

to class imbalance- the dominance of the non-gastric cancer class, and was also reported with

95% confidence interval. A higher AP score is indicative of better performance in correctly

classifying the minority class. Additionally, a confusion matrix was plotted for both raw counts

and percentages per cell, annotated with accuracy, sensitivity and specificity values. Calibration

quality was quantified using Brier scores, with lower scores indicating that the model's predicted

probabilities were closer to the true outcome frequencies and therefore better calibrated.

2.12 Post-hoc Explanation:

To interpret model predictions and understand the contribution of each feature, post-hoc

explainability techniques were performed using SHAP Python package (version 0.47.1). The

average impact of each feature on the model's output was visualized using SHAP summary plots

for the three models (Logistic Regression (baseline), XGBoost, and Random Forest). In addition

to global explanations, local explanations were generated for specific test samples using SHAP

waterfall plots. These plots decomposed an individual prediction into contributions from each

feature relative to the model's expected value, with the explained class chosen as either the

model's predicted class or a user-specified class index (0 for gastric cancer, 1 for non-gastric

cancer). For each explained sample, the predicted class label and corresponding predicted

probabilities for both classes were reported. These plots were used to illustrate the global and

local feature importance across the whole dataset. These explainability techniques aid

interpretation of models and help in assessing the consistency of feature contributions across

different models.

3. Results:

Classification models were developed to group subjects into the gastric cancer and non-gastric

cancer classes.

Logistic Regression was used as a baseline classifier to evaluate initial predictive performance

on the binary classification task of gastric cancer vs non-gastric cancer. On applying

oversampling using SMOTENC, the confusion matrix (Figure 2D) revealed that the model

correctly classified 61 out of 83 gastric cancer cases (73.5% sensitivity) and 161 out of 190 non-

gastric cancer cases (84.7% specificity). The model produced 22 false negatives (26.5% of

gastric cancer cases misclassified as non-gastric) and 29 false positives (15.3% of non-gastric

cancer cases misclassified as gastric), resulting in an overall accuracy of 0.813 (95% CI: 0.766-

0.864). The model displayed balanced performance across key metrics (Figure 2C), with

precision values of 0.683 (95% CI: 0.591-0.784) for gastric cancer and 0.880 (95% CI: 0.831-

0.928) for non-gastric cancer classification.

Figure 2: Logistic Regression model performance for gastric cancer vs non-gastric cancer

classification. (A) ROC curve showing discriminative ability with AUC of 0.888 (95% CI:

0.843-0.929). (B) Precision-recall curves for both gastric cancer (AUPRC = 0.832, 95% CI:

0.762-0.893) and non-gastric cancer (AUPRC = 0.941, 95% CI: 0.909-0.967) classes. (C)

Classification performance metrics comparing F1-score, recall, and precision between gastric

and non-gastric cancer predictions. (D) Confusion matrix displaying true versus predicted labels

with overall accuracy of 81.3%, sensitivity of 73.5%, and specificity of 84.7%.

The recall performance showed class-specific differences, with gastric cancer class recall of

0.736 (95% CI: 0.644-0.831), and non-gastric cancer recall of 0.849 (95% CI: 0.797-0.900). This

resulted in F1-scores of 0.707 (95% CI: 0.623-0.784) and 0.849 (95% CI: 0.822-0.901) for

gastric and non-gastric cancer classes respectively (Figure 2C). The model also achieved a good

AUPRC of 0.832 (95% CI: 0.762-0.893) for gastric cancer and 0.941 (95% CI: 0.909-0.967) for

non-gastric cancer classes (Figure 2B). The discriminatory power of the model denoted by an

AUROC of 0.888 (95% CI: 0.843-0.929) was equal for both the classes. These findings are

illustrated in Figure 2A. Detailed performance metrics with CIs are provided in Supplementary

Table S6 and the classification report of the model is provided in Supplementary Table S7.

Overall, logistic regression proved to be a reasonable baseline with good performance. The lower

recall for gastric cancer detection (73.6%) shows the necessity for more complex models that

enhance the detection of the minority gastric-cancer class. Model calibration analysis showed

reasonable probability confidence with a Brier score of 0.125 (Supplementary Figure S1).

Building on the baseline logistic regression model's performance, we evaluated two black-box

models: XGBoost and Random Forest to improve the detection of gastric cancer.

Prior to model training, feature selection was performed using ShapRFECV with cross validation

to identify the most informative features for gastric cancer classification. The feature selection

reduced the initial feature set from 533 to 93 features, with the optimal subset determined

through 10-fold cross validation based on recall scores (Supplementary Table S8).

Hyperparameter optimization was conducted using bayesian optimization with 10-fold cross

validation for both the black-box models. For XGBoost, the optimal parameters were:

n_estimators=1000, max_depth=7, colsample_bytree=1.0, subsample=0.601, and

learning_rate=0.0279. Random Forest achieved optimal performance with n_estimators=955,

max_depth=10, and min_samples_split=3. Complete hyperparameter configurations are provided

in Supplementary Table S9.

Figure 3: Performance evaluation of XGBoost model for gastric cancer vs non-gastric

cancer classification. (A) ROC curve demonstrating superior discriminative performance with

AUC of 0.950 (95% CI: 0.925-0.971). (B) Precision-recall curves showing excellent

performance for both gastric cancer (AUPRC = 0.906, 95% CI: 0.855-0.948) and non-gastric

cancer (AUPRC = 0.978, 95% CI: 0.964-0.988) classes. (C) Classification metrics revealing high

F1-scores, recall, and precision across both classes. (D) Confusion matrix indicating improved

classification accuracy of 88.6%, sensitivity of 79.5%, and specificity of 92.6%

XGBoost displayed superior performance over the baseline, with the confusion matrix revealing

correct classification of 66 out of 83 gastric cancer cases (79.5% sensitivity) and 176 out of 190

non-gastric cancer cases (92.6% specificity). The model produced 17 false negatives (20.5% of

gastric cancer cases misclassified as non-gastric) and 14 false positives (7.4% of non-gastric

cancer cases misclassified as gastric), resulting in an overall accuracy of 0.886 (95% CI: 0.850-

0.920) as shown in Figure 3D. The model displayed excellent performance across key metrics,

with precision values of 0.829 (95% CI: 0.750-0.907) and 0.912 (95% CI: 0.871-0.950) for

gastric and non-gastric cancer classes respectively. The recall performance showed improved

gastric cancer detection at 0.797 (95% CI: 0.711-0.877) and maintained high non-gastric cancer

recall of 0.927 (95% CI: 0.889-0.960). This resulted in F1-scores of 0.812 (95% CI: 0.745-0.871)

and 0.919 (95% CI: 0.891-0.945) for gastric and non-gastric cancer classes respectively (Figure

3C). The model achieved strong AUPRC values of 0.906 (95% CI: 0.855-0.948) for gastric

cancer and 0.978 (95% CI: 0.964-0.988) for non-gastric cancer classes (Figure 3B). The

discriminatory power denoted by an AUROC of 0.950 (95% CI: 0.925-0.971) exceeded the

baseline performance (Figure 3A).

Figure 4: Performance evaluation of Random Forest model for gastric cancer vs non-

gastric cancer classification. (A) ROC curve showing excellent discriminative capacity with

AUC of 0.954 (95% CI: 0.929-0.976). (B) Precision-recall curves demonstrating robust

performance for gastric cancer (AUPRC = 0.926, 95% CI: 0.888-0.959) and non-gastric cancer

(AUPRC = 0.978, 95% CI: 0.961-0.990) classification. (C) Classification performance metrics

indicating balanced precision and recall across both classes. (D) Confusion matrix showing the

highest overall accuracy of 89.7%, with sensitivity of 81.9% and specificity of 93.2%.

Random Forest achieved the highest overall performance among all tested models, with the

confusion matrix showing correct classification of 68 out of 83 gastric cancer cases (81.9%

sensitivity) and 177 out of 190 non-gastric cancer cases (93.2% specificity). The model produced

15 false negatives (18.1% of gastric cancer cases misclassified as non-gastric) and 13 false

positives (6.8% of non-gastric cancer cases misclassified as gastric), resulting in an overall

accuracy of 0.897 (95% CI: 0.861-0.930) as shown in Figure 4D. The model displayed excellent

balanced performance across key metrics, with precision values of 0.841 (95% CI: 0.753-0.912)

for gastric cancer and 0.922 (95% CI:0.881-0.957) for non-gastric cancer classification. The

recall performance displayed the highest gastric cancer detection at 0.820 (95% CI: 0.734-0.896)

and robust non-gastric cancer recall of 0.932 (95% CI: 0.897-0.963). This resulted in F1-scores

of 0.830 (95% CI: 0.767-0.886) and 0.926 (95% CI: 0.898-0.951) for gastric and non-gastric

cancer classes respectively (Figure 4C). The model achieved excellent AUPRC values of 0.926

(95% CI: 0.888-0.959) for gastric cancer and 0.978 (95% CI: 0.961-0.990) for non-gastric cancer

classes (Figure 4B). The discriminatory power denoted by an AUROC of 0.954 (95% CI: 0.929-

0.976) was the highest among all tested models (Figure 4A). Detailed performance metrics with

confidence intervals are provided in Supplementary Table S6 and the classification report is

provided in Supplementary Table S7.

Both black-box models outperformed the baseline, with Random Forest achieving superior

performance in gastric cancer detection (sensitivity: 82.0% vs 79.7% for XGBoost vs 73.6% for

baseline) and overall accuracy (89.7% vs 88.6% vs 81.3% respectively). Model calibration

analysis revealed improved probability confidence for both black-box models, with XGBoost

achieving a Brier score of 0.087 and Random Forest achieving 0.078 after calibration,

representing 30% and 38% improvements over the baseline score of 0.125 respectively

(Supplementary Figure S2 and S3). The superior performance of both black-box models,

particularly Random Forest's enhanced gastric cancer detection capability, demonstrates the

effectiveness of tree-based algorithms for this complex classification task.

DeLong's test was performed to statistically evaluate the differences between the areas under

two ROC curves derived from distinct models. The difference in the AUROC of

XGBoostClassifier and the baseline Logistic Regression was statistically significant with a p-

value equal to 0.0017 and Z score equal to -3.13. Similarly, the difference in AUROC of

Random Forest and the baseline Logistic Regression was statistically significant with a p-value

of 0.0013 and Z score of -3.20. Both black-box models displayed statistically significant

improvements over the baseline logistic regression model.

3.1 Model Explanations:

The global SHAP summary plots provide post-hoc global explanations of the model to identify

the features that contributed most to the model's predictions.

Figure 5. SHAP (SHapley Additive exPlanations) analysis of logistic regression model

interpretability. (A) Global feature importance showing the mean absolute SHAP values across

all features, with Age (0.60) and Continent_Europe (0.52) as the most influential predictors,

while 539 additional features collectively contribute 23.8 to model predictions. (B) Individual

prediction explanation for Sample 2 (f(x) = -3.647, E[f(X)] = 0.717) demonstrating how specific

feature values contribute toward non-gastric cancer prediction (red bars, positive values) or

gastric cancer prediction (blue bars, negative values), with the overall negative prediction score

indicating classification toward gastric cancer (class 0).

In the case of the baseline logistic regression model, the model primarily relied on demographic

variables, with Age as the most influential predictor, followed by Continent (Asia and Europe).

Aggregate variant categories such as start_retained_variant, intergenic_region and other

combinations of different variant categories also contributed, though with moderate impact

(Figure 5A). Sequence-derived features such as k-mers, Z-curve were not in the top 10

influential features for the baseline model.

Figure 6. SHAP analysis revealing feature importance and prediction explanations for the

XGBoost model. (A) Global feature importance highlighting Age (0.99) as the dominant

predictor, followed by CAC (0.62) and frameshift_variant (0.37), with 84 other features

contributing 9.27 collectively. (B) Individual prediction explanation for Sample 2 (f(x) = -4.471,

E[f(X)] = 0.216) showing how CAC (-0.66), frameshift variants (-0.63), and age-related features

(-0.52) drive the prediction strongly toward gastric cancer (class 0), while some variants

categories provide modest contributions toward non-gastric cancer classification.

The XGBoost model captured a combination of demographic, aggregate variant categories and

sequence-derived features. Age was the top predictor here too followed by a sequence-derived

feature CAC k-mer. Among variant categories, frameshift_variant and

frameshift_variant&stop_lost had considerable contributions, while other sequence k-mers such

as AGC, ATA, and GTA also ranked highly. In addition to the above mentioned features, Z-

curve descriptors (Zcurve144_1_CA.y and Zcurve144_3_AA.z) appeared among the top 10

influential predictors, suggesting that genome composition features provided additional

discriminatory power (Figure 6A).

Figure 7. SHAP analysis demonstrating the interpretability of the Random Forest model

predictions. (A) Global feature importance showing relatively balanced feature contributions

with Age (0.05), CAC (0.03), and MMI_AT (0.02) as leading predictors, and 84 other features

contributing 0.33 collectively, indicating more distributed feature utilization compared to other

models. (B) Individual prediction explanation for Sample 2 (f(x) = 0.624, E[f(X)] = 0.5)

revealing subtle feature contributions, with splice_region_variant providing influence toward

gastric cancer (-0.05) and CAC contributing toward non-gastric cancer (+0.04), with the overall

positive prediction score indicating classification toward non-gastric cancer (class 1).

Similar to XGBoost, Age and CAC k-mer were the top predictors, indicating their consistent

importance across models. The Random Forest also emphasized sequence descriptors, such as

MMI_AT, CAA, and CKSNAP_TA.gap2, alongside variant categories like

frameshift_variant&stop_lost&splice_region_variantstop_retained_variant and

disruptive_inframe_deletion&synonymous_variant. Additional k-mers (ATA, AGA) and

structural variant categories (for e.g., conservative_inframe_insertion) contributed, though with

smaller SHAP values compared to Age and CAC (Figure 7A).

Across all models, age consistently emerged as the most influential predictor, while

Continent_Europe was particularly important in the Logistic Regression model. Tree-based

classifiers (XGBoost and Random Forest) captured a broader range of sequence k-mers and

variant categories, suggesting they were better able to integrate complex genomic patterns along

with demographic features.

To interpret individual-level predictions, we generated SHAP waterfall plots for representative

test samples that were classified as gastric cancer (positive class, encoded as 0) by each model.

These plots illustrate how genomic and demographic features contributed positively or

negatively to the probability of gastric cancer in correctly predicted cases.

The logistic regression model relied heavily on combined variant types, with

stop_lost&disruptive_inframe_deletion&synonymous_variant and geographic factor (patient not

being from Continent_Europe) as primary features that contribute to gastric cancer classification.

The 539 aggregated features contributed substantially, while

splice_region_variant&stop_retained_variant provided the strongest opposing influence (Figure

5B).

The XGBoost model emphasized sequence composition, with CAC and

frameshift_variant&start_lost as top contributors toward gastric cancer prediction. Z-curve

parameter, Zcurve144_3_AA.z, age, and k-mer GAC played a significant role. The 84

aggregated features showed strong gastric cancer contribution, while

splice_region_variant&stop_retained_variant, disruptive_inframe_deletion, and

Zcurve144_1_AC.x contributed to the non-gastric cancer class (Figure 6B).

The Random Forest model showed variant categories pushing the classification towards the

gastric cancer class with splice_region_variant&stop_retained_variant being a comparatively

strong contributor, while the remaining variant categories such as

conservative_inframe_insertion and disruptive_inframe_deletion&synonymous_variant show

moderate contributions. Genome composition features like Z-curve descriptors

(Zcurve144_1_AC.x) also contributed to the gastric cancer class (Figure 7B).

4. Discussion:

Three machine learning algorithms were used to identify primarily genomic variables that contributed to the development of gastric cancer in individuals infected with *H. pylori*. In order to be inclusive and accessible to clinicians, white-box models were used in addition to high-performance black-box machine learning models. A variety of explainability measures like SHAP were also utilized to explain identified associations and increase clinician confidence, and this framework was designed to uncover dynamic genomic risk factors and supplement clinician decision-making. This is demonstrably superior to traditional modeling methods which are constrained by the number of variables that can be incorporated into the study and unable to unearth complex associations.

It can be seen that age was consistently identified as the top predictor of gastric cancer across all three models. This aligns with existing scientific literature implicating older patients as more susceptible to developing gastric cancer, with around 6 out of every 10 people diagnosed with gastric cancer being 65 years or older[30] .

The top 3 predictors in the baseline model were age, belonging to Europe and silent mutations in the start codons (Figure 5A). Fatality linked to gastric cancer has been shown to be particularly high in regions of East Asia and Eastern Europe[31]. The malignancy of certain geographical strains could be in part due to differences in virulence genotypes like *cagA* motifs[32]. The silent mutations in the start codon could lead to the production of proteins with altered functional properties, thus influencing the malignancy of the *H. pylori* strain.

The top 3 contributing factors in the XGBoost model were age, the reverse kmer CAC and the simultaneous presence of frameshift mutations and loss of stop codons (Figure 6A). The

presence of the trinucleotide CAC could be indicative of distinctive pathogenicity islands or

similar genomic signatures associated with *H. pylori* infection and adaptation. Stop codons have

also been implicated in existing literature, with a study depicting the loss of expression of the

virulence gene BabA due to a mutation resulting in a stop codon being acquired[33]. The loss of

stop codons could be likely to capture phase variation events that control the expression of key

infection factors and thus influencing gastric cancer risk.

The top 3 contributing factors in the Random Forest model were age, the reverse kmer CAC and

the presence of AT rich regions (Figure 7A). While the first two features were also the most

important in the XGBoost model, multivariate mutual information aids in capturing higher-order

nucleotide correlations beyond regular k-mer counts. The high correlation with AT could

indicate the difference in the degree of sequence-order through structured repeats and conserved

motifs between cancer-associated and benign strains.

The two black-box models also consistently identified the presence of the CAC, ATA and AAA

reverse kmers as associated with increased discriminatory power between infection outcomes.

Combinations of variants have also been marked as gastric-cancer inducing factors in both the

XGBoost and Random Forest models, such as the high presence of all 4 mutations- frameshift

variants, loss of stop codons, missense variants and splice region variants. These variants result

in an alteration of amino acids in bacterial proteins, and could reflect divergent strains, altered

virulence factors and genetic plasticity. Previous studies have found that many common allelic

variants are more frequent in outer-membrane associated virulence genes, like *sabA* and *babA*[34].

Besides corroborating existing literature on the causative risk factors of malignant *H. pylori*

infection induced gastric cancer and thus establishing itself as reliable, our study can also

advance research that seeks to detect and mitigate *H. pylori* outcomes through personalized

treatment approaches. Further studies that seek to investigate causal inference between identified

features can also make use of our explainable machine learning framework. Although the models

possessed remarkable discriminatory power, a variety of pertinent features were not incorporated

into the model. It has been shown that family history, smoking habits, diet and other clinical

features play a very important role in the development of *H. pylori* infection associated

outcomes, along with the role of host immune factors[35]. The data also had a large number of

European samples (870), and since the data was publicly available, there could have been

varying biases introduced at different stages of data collection like participation bias, and the

lack of inclusion of control patients without *H. pylori* infection. Access to more diverse data

sources, particularly from the Global South, could mitigate existing geographic bias and render

the model more generalizable.

5. Conclusions:

Integrating machine learning with bedside treatment will be a significant stride in early detection

and personalized diagnostic methods for identifying the severity of *H. pylori* infection responses.

In an attempt to improve clinical trust in black-box models, explainable AI was used to break

down top features to improve transparency. Among the evaluated models, the two black-box

models achieved greater recall in the prediction of gastric cancer compared to the baseline

logistic regression model. The top predictor was consistently found to be patient age across all

three models, while different genomic markers were identified by each of the models.

Incorporating genomic features of the host along with clinical metadata could enhance the

predictive power and the robustness of the models since current *H. pylori* prediction models

focus largely on clinical features. As gene expression plays a major role in the development of

infection, integration of transcriptomic data and host gut metagenomic data could account for

gene expression and interaction of *H. pylori* with other gut microbes. The sequence-derived

genomic features implicated in this study open avenues for further research into the *H. pylori*

genome beyond the already implicated virulence genes to assess possible causation behind the

associations found in this study. Assimilating real-time data gathering options for the model

through collaboration with medical centres, incorporating clinical feedback loops and refining

the user interface can render it a powerful tool for spontaneous risk-assessment and bolster

regional health infrastructure. The high accuracy of our research model in discriminating

between severe and benign *H. pylori* infection outcomes underscore its potential impact in

deploying it in resource-limited populations that are disproportionately plagued by *H. pylori*

infections.

6. List of abbreviations

H. pylori: *Helicobacter pylori*

XGBoost: eXtreme Gradient Boosting

SMOTE-NC: Synthetic Minority Over-sampling Technique for Nominal and Continuous

SHAP: SHapley Additive exPlanations

AUROC: Area Under Receiver Operating Characteristic curve

MALT: Mucosa-associated lymphoid tissue

WHO: World Health Organisation

cagA: cytotoxin-associated gene A

cagPAI: cag pathogenicity island

vacA: vacuolating cytotoxin A

BabA: blood group antigen binding adhesin

oipA: outer inflammatory protein A

sLe^X : sialylated Lewis antigens

SRA: Sequence Read Archive

NAC: Nucleic Acid Composition

MMI: Multivariate Mutual Information

ROC: Receiver Operating Characteristic

AUC: Area Under the Curve

AUPRC: Area Under the Precision-Recall curve

AP: Average precision

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The *Helicobacter pylori* genomes analyzed in this study are publicly available on the National

Center for Biotechnology Information (NCBI) GenBank repository

(https://www.ncbi.nlm.nih.gov/genbank/) and EnteroBase (https://enterobase.warwick.ac.uk/).

Accession numbers for all 1,363 genomes used in analyses are provided in Supplementary Table

1. The custom code and analysis pipelines used in this study are available on GitHub

(https://github.com/Venkatesh-99/HP_ML/) and archived in Zenodo at

(https://doi.org/10.5281/zenodo.17085927).

Competing interests

The authors declare that they have no competing interests.

Funding

No funding source was utilized in carrying out this study.

Author Contributions Statement:

SPW and VN contributed equally to conceptualization, data curation, investigation and

methodology design, software and formal analysis, data visualization, validation, writing the

original draft, reviewing and editing the manuscript. MPT contributed to data curation and

formal analysis. JJJ, NV and GGT contributed to conceptualization, reviewing and editing the

manuscript. BV contributed to reviewing and editing the manuscript, provision of resources,

project administration and supervision. All authors read and approved the final manuscript.

Acknowledgements:

Not applicable

<u>References:</u>

1. Shatila, M. & Thomas, A. S. Current and Future Perspectives in the Diagnosis and

Management of Helicobacter pylori Infection. *J. Clin. Med.* **11**, 5086 (2022).

2. Elbehiry, A. *et al.* Helicobacter pylori Infection: Current Status and Future Prospects on

Diagnostic, Therapeutic and Control Challenges. *Antibiot. Basel Switz.* **12**, 191 (2023).

3. Pucułek, M. *et al.* Helicobacter pylori associated factors in the development of gastric cancer

with special reference to the early-onset subtype. *Oncotarget* **9**, 31146–31162 (2018).

4. Backert, S. & Blaser, M. J. The Role of CagA in the Gastric Biology of Helicobacter pylori.

Cancer Res. **76**, 4028–4031 (2016).

5. Kao, C.-Y., Sheu, B.-S. & Wu, J.-J. Helicobacter pylori infection: An overview of bacterial

virulence factors and pathogenesis. *Biomed. J.* **39**, 14–23 (2016).

6. McClain, M. S., Beckett, A. C. & Cover, T. L. Helicobacter pylori Vacuolating Toxin and

Gastric Cancer. *Toxins* **9**, 316 (2017).

7. Foegeding, N. J., Caston, R. R., McClain, M. S., Ohi, M. D. & Cover, T. L. An Overview of

Helicobacter pylori VacA Toxin Biology. *Toxins* **8**, 173 (2016).

8. González, C. A. *et al.* Helicobacter pylori cagA and vacA genotypes as predictors of

progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in

Spain. *Am. J. Gastroenterol.* **106**, 867–874 (2011).

9. Fujimoto, S. *et al.* Helicobacter pylori BabA expression, gastric mucosal injury, and clinical

outcome. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **5**, 49–

58 (2007).

10. Gerhard, M. *et al.* Clinical relevance of the Helicobacter pylori gene for blood-group

antigen-binding adhesin. *Proc. Natl. Acad. Sci. U. S. A.* **96**, 12778–12783 (1999).

11. Chiarini, A. *et al.* Prevalence of virulence-associated genotypes of Helicobacter pylori and

correlation with severity of gastric pathology in patients from western Sicily, Italy. *Eur. J.*

Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. **28**, 437–446 (2009).

12. Teymournejad, O., Mobarez, A. M., Hassan, Z. M. & Talebi Bezmin Abadi, A. Binding of

the Helicobacter pylori OipA causes apoptosis of host cells via modulation of Bax/Bcl-2

levels. *Sci. Rep.* **7**, 8036 (2017).

13. Dossumbekova, A. *et al.* Helicobacter pylori HopH (OipA) and bacterial pathogenicity:

genetic and functional genomic analysis of hopH gene polymorphisms. *J. Infect. Dis.* **194**,

1346–1355 (2006).

14. Zambon, C.-F., Navaglia, F., Basso, D., Rugge, M. & Plebani, M. Helicobacter pylori

babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. *J.*

Clin. Pathol. **56**, 287–291 (2003).

15. Markovska, R., Boyanova, L., Yordanov, D., Gergova, G. & Mitov, I. Helicobacter pylori

oipA genetic diversity and its associations with both disease and cagA, vacA s, m, and i

alleles among Bulgarian patients. *Diagn. Microbiol. Infect. Dis.* **71**, 335–340 (2011).

16. Ando, T. *et al.* Polymorphisms of Helicobacter pylori HP0638 reflect geographic origin and

correlate with cagA status. *J. Clin. Microbiol.* **40**, 239–246 (2002).

17. Oleastro, M. *et al.* Evaluation of the clinical significance of homB, a novel candidate marker

of Helicobacter pylori strains associated with peptic ulcer disease. *J. Infect. Dis.* **198**, 1379–

1387 (2008).

18. Hage, N. *et al.* Structural basis of Lewis(b) antigen binding by the Helicobacter pylori

adhesin BabA. *Sci. Adv.* **1**, e1500315 (2015).

19. Doohan, D., Rezkitha, Y. A. A., Waskito, L. A., Yamaoka, Y. & Miftahussurur, M.

Helicobacter pylori BabA-SabA Key Roles in the Adherence Phase: The Synergic

Mechanism for Successful Colonization and Disease Development. *Toxins* **13**, 485 (2021).

20. Unemo, M. *et al.* The sialic acid binding SabA adhesin of Helicobacter pylori is essential for

nonopsonic activation of human neutrophils. *J. Biol. Chem.* **280**, 15390–15397 (2005).

21. Perna, A. M. *et al.* Fragment-Based De Novo Design Reveals a Small-Molecule Inhibitor of

Helicobacter Pylori HtrA. *Angew. Chem. Int. Ed Engl.* **54**, 10244–10248 (2015).

22. Hoy, B. *et al.* Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-

cadherin to disrupt intercellular adhesion. *EMBO Rep.* **11**, 798–804 (2010).

23. Dadashzadeh, K., Peppelenbosch, M. P. & Adamu, A. I. Helicobacter pylori Pathogenicity

Factors Related to Gastric Cancer. *Can. J. Gastroenterol. Hepatol.* **2017**, 7942489 (2017).

24. Leylabadlo, H. E., Yekani, M. & Ghotaslou, R. Helicobacter pylori hopQ alleles (type I and

II) in gastric cancer. *Biomed. Rep.* **4**, 601–604 (2016).

25. Malfertheiner, P. *et al.* Helicobacter pylori infection. *Nat. Rev. Dis. Primer* **9**, 19 (2023).

26. Alm, R. A. & Noonan, B. The Genome. in *Helicobacter pylori: Physiology and Genetics*

(eds Mobley, H. L., Mendz, G. L. & Hazell, S. L.) (ASM Press, Washington (DC), 2001).

27. Taninaga, J. *et al.* Prediction of future gastric cancer risk using a machine learning algorithm

and comprehensive medical check-up data: A case-control study. *Sci. Rep.* **9**, 12384 (2019).

28. Jiang, S. *et al.* Machine learning: A non-invasive prediction method for gastric cancer based

on a survey of lifestyle behaviors. *Front. Artif. Intell.* **5**, (2022).

29. Afrash, M. R., Shafiee, M. & Kazemi-Arpanahi, H. Establishing machine learning models to

predict the early risk of gastric cancer based on lifestyle factors. *BMC Gastroenterol.* **23**, 6

(2023).

30. Jeon, M., Jang, H., Jeon, H., Park, C. G. & Kim, S. Long-term late effects in older gastric

cancer survivors: Survival analysis using Cox hazard regression model by retrospective

electronic health records. *Support. Care Cancer* **32**, 29 (2024).

31. Grantham, T. *et al.* Epidemiology of Gastric Cancer: Global Trends, Risk Factors and

Premalignant Conditions. *J. Community Hosp. Intern. Med. Perspect.* **13**, 100–106 (2023).

32. Ahn, H. J. & Lee, D. S. Helicobacter pylori in gastric carcinogenesis. *World J. Gastrointest.*

Oncol. **7**, 455–465 (2015).

33. Styer, C. M. *et al.* Expression of the BabA Adhesin during Experimental Infection with

Helicobacter pylori. *Infect. Immun.* **78**, 1593–1600 (2010).

34. Wilkinson, D. J., Dickins, B., Robinson, K. & Winter, J. A. Genomic diversity of

Helicobacter pylori populations from different regions of the human stomach. *Gut Microbes*

14, 2152306 (2022).

35. Öztekin, M., Yılmaz, B., Ağagündüz, D. & Capasso, R. Overview of Helicobacter pylori

Infection: Clinical Features, Treatment, and Nutritional Aspects. *Dis. Basel Switz.* **9**, 66

(2021).

Additional files:

File name:

Additional file 1

File format:

.xlsx (Microsoft Excel Spreadsheet)

Title of data:

Supplementary Tables S1-S9: Features used, detailed model metrics, optimal hyperparameters

Description of data:

• Supplementary Table S1: Clinical metadata of the patients. Includes patient

demographics like their age, sex, their geographical location and the disease phenotype.

• Supplementary Table S2: Presence/absence data of *H. pylori* virulence genes implicated

in gastric cancer

• Supplementary Table S3: Sequence-derived features extracted from *H. pylori* genomes

using iFeatureOmega and MathFeature

• Supplementary Table S4: Aggregate variant categories of *H. pylori* genomes

• Supplementary Table S5: The final all feature-types integrated dataset

• Supplementary Table S6: Detailed evaluation metrics for all three models with class-

specific precision, recall, F1-score, AUROC and AUPRC scores with lower and upper

confidence intervals

• Supplementary Table S7: Classification reports of all three models

●   Supplementary Table S8: ShapRFECV feature elimination report. Contains information

about the selected and eliminated features based on the recall metric

●   Supplementary Table S9: Optimal hyperparameters selected using Bayesian optimization

for XGBoost and Random Forest models

File name:

Additional file 2

File format:

.png (Portable Network Graphics image)

Title of data:

Calibration plot of logistic regression classifier

Description of data:

This figure shows the calibration performance of the logistic regression model for predicting

gastric cancer. The fraction of positives is plotted against the mean predicted probability, with

the dashed diagonal line representing perfect calibration. The Brier score is provided as a

summary measure of calibration accuracy.

File name

Additional file 3

File format

.png (Portable Network Graphics image)

Title of data

Calibration plots of extreme gradient boosting (XGBoost) classifier before and after calibration

Description of data

This figure presents side-by-side calibration plots of the XGBoost classifier before and after

calibration. Each plot shows the fraction of positives against mean predicted probability, with the

dashed diagonal line representing perfect calibration. Brier scores before and after calibration are

included to quantify improvement in model calibration.

File name

Additional file 4

File format

.png (Portable Network Graphics image)

Title of data

Calibration plots of random forest classifier before and after calibration

Description of data

This figure shows the calibration performance of the random forest classifier, with separate

panels for before and after calibration. Each plot compares predicted probabilities with observed

outcomes, with the diagonal line indicating perfect calibration. Brier scores are reported to

demonstrate changes in calibration accuracy following adjustme

Data Collection and Quality Control

Feature Extraction and Data Preprocessing

Model Training, Evaluation and Explanation

Logistic Regression Evaluation

A. ROC Curve

B. Precision-Recall Curve

Gastric cancer - AUPRC = 0.832 (95% CI: 0.762–0.893)
Non-gastric cancer - AUPRC = 0.941 (95% CI: 0.909–0.967)

C. Classification Metrics

Gastric cancer
Non-gastric cancer

D. Confusion Matrix

Accuracy: 0.813 | Sensitivity: 0.735 | Specificity: 0.847

XGBoost Evaluation

Accuracy: 0.886 | Sensitivity: 0.795 | Specificity: 0.926

A **Global Feature Importance**

B **Individual Prediction Explanation - Sample 2**

A **Global Feature Importance**

B **Individual Prediction Explanation - Sample 2**

A **Global Feature Importance**

B **Individual Prediction Explanation - Sample 2**